Skip to content

Blood concentrations of efavirenz predict who will develop central nervous system side-effects

Tipranavir receives European marketing approval

Are atazanavir levels reduced by antacids?

Side-effects major reason UK patients switch from first-line therapy, BHIVA audit finds

CD4 cell count below 250 associated with shorter treatment break

New boosted PIs should be used with T-20 for maximum impact, say new US guidelines

Zimbabwe teachers urge free ARVs as AIDS thins their ranks

Safety review board gives go-ahead for studies into Pfizer's CCR5 inhibitor to continue as planned

NNRTI-resistant HIV most frequently transmitted mutation in Spain, but overall prevalence low